Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40

American Journal of Surgery

Volumn 179, Issue 5, 2000, Pages 400-406

  Ramstad, Trygg ^a   Lawnicki, Lyle ^b   Vetto, John ^c   Weinberg, Andrew ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Section of Surgical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ARTICLE; AXILLARY LYMPH NODE; BREAST TUMOR; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; T LYMPHOCYTE; TUMOR CELL;

ANTIGENS, CD27; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0034656871     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(00)00361-5     Document Type: Article

References (36)

1. Chu Y., Hu H.-M., Winter H., et al. Examining the immune response in sentinel lymph nodes in mice and men. Eur J Immunol. 26:(suppl):1999;S50-S53.
2. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. NEJM. 313:1985;1485-1492.
3. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant interferon alpha-2a, or both in metastatic renal cell carcinoma. NEJM. 998;338:1272-1278.
4. West W.H., Tauer K.W., Yannelli J.R., et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. NEJM. 316:1987;898-905.
5. Rosenberg S.A. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Ann Rev Med. 47:1996;481-491.
6. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 4:1998;321-327.
7. Weinberg A.D., Rivera M.M., Prell R., et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol. 164:2000;2160-2169.
8. Calderhead D.M., Buhlmann J.E., van den Eertwegh A.J.M., et al. Cloning of mouse OX-40 a T cell activation marker that may mediate T-B cell interactions . J Immunol. 151:1993;5261-5271.
9. Weinberg A.D., Vella A.T., Croft M. OX-40 life beyond the effector T cell stage . Semin Immunol. 10:1998;471-480.
10. Vetto J.T., Lum S., Morris A., et al. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg. 174:1997;258-265.
11. Granaglia I., Weinberg A., Lemmon L., Croft M. OX-40 ligand a potent costimulatory molecule for sustaining primary CD4 T cell responses . J Immunol. 161:1998;6510-6517.
12. Weinberg A.D., Lemon M., Jones A.J., et al. OX-40 antibody enhances for autoantigen specific Vβ8.2+ T-cells within the spinal cord of Lewis rats with autoimmune enchephalomyelitis. J Neurosci Res. 43:1996;42-49.
13. Tittle T.V., Weinberg A.D., Stienkeler C.N., Maziarz R.T. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T-cells in acute graft-versus-host disease. Blood. 89:1997;4652-4658.
14. Weinberg A.D., Bourdette D.N., Sullivan T.J., et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med. 2:1996;183-189.
15. + spinal cord of Lewis rats with EAE. J Neurosci Res. 44:1996;562-567.
16. Weinberg A.D., Wegmann K.W., Funatake C., Whitman R.H. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol. 162:1999;1818-1826.
17. Higgins L.M., McDonald S.A.C., Whittle N., et al. Regulation of T Cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein . J Immunol. 162:1999;486-493.
18. Davies H.A. General preparation of material and staining of sections. Meth Mol Bio. 117:1999;1-11.
19. Latza U., Durkop H., Schinittger S., Ringeling J. The human OX-40 homolog cDNA structure, expression, and chromosomal assignment of the ACT35 antigen . Eur J Immunol. 24:1994;677-683.
20. Bazzoni F., Beutler B. The tumor necrosis ligand and receptor families. NEJM. 334:1996;1717-1725.
21. Ohsima Y., Tanaka Y., Tozawa H., et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 159:1997;3838-3848.
22. Stuber E., Neurath M., Calderheard D., et al. Crosslinking of OX-40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic cells. Immunity. 2:1995;507-521.
23. Imura A., Hori T., Imanda K., et al. The human OX-40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med. 183:1996;2185-2195.
24. Godfrey WR, Fagnoni FF, Harara MA, et al. Identification of a human OX40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med. 1994180:757-576.
25. Stuber E., Stober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humor immune response. J Exp Med. 183:1996;979-989.
26. Walker L.S.K., Gulbranson-Judge A., Flynn S. et al. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J Exp Med. 190:1999;1115-1122.
27. Lynch D.H., Ramsdell F., Alderson M.R. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today. 16:1995;569-574.
28. + T cells. Int Immunol. 10:1998;453-461.
29. Matsui S., Ahlers J.D., Vortmeyer A.O., et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol. 163:1999;184-193.
30. Whitford P., George W.D., Campbell A.M. Flow cytometric analysis of tumor infiltrating lymphocyte activation and tumor cell MHC I and II expression in breast cancer patients. Cancer Lett. 61:1992;157-164.
31. Shurin M.R. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother. 43:1996;158-164.
32. Gutierrez L.S., Eliza M., Niven-Fairchild T., et al. The Fas/Fas-ligand system a mechanism for immune evasion in human breast cancer . Breast Can Res. 54:1999;245-253.
33. Salazar-Onfray F. Interleukin-10 a cytokine used by tumors to escape immunosurveillance . Med Oncol. 16:1999;86-94.
34. Ungefroren H., Voss M., Berstorff W.V., et al. Immunological escape mechanisms in pancreatic carcinoma. Ann NY Acad Sci. 880:1999;243-251.
35. Maeuer M.J., Gollin S.M., Storkus W.J., et al. Tumor escape from immune recognition loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6 . Clin Cancer Res. 2:1996;641-652.
36. + T cell responses. Ann Rev Immunol. 15:1997;297-322.